Blackstone Labs | BS Labs Abnormal 1 | 2-Product Stack

Blackstone Labs Abnormal 1 Stack, based on the verified label available, is fundamentally a 19-NorDHEA prohormone formula built around one job: delivering a 19-nor androgen precursor in a compact once-daily tablet format. This is not a conventional sports nutrition product like a pre-workout, creatine, or recovery agent. It sits in the hormone-support/prohormone category, where the buying decision should be made with a clear understanding of what the formula is designed to do, what it does not do, and what risks come with that category.

The active panel is a 50mg proprietary 19-NorDHEA Blend containing 19-NorAndrost-4-ene-3b-ol, 17-one plus decanoate and enanthate forms of the same core compound. 19-NorDHEA is used as a precursor in the 19-nor anabolic pathway and is marketed for physique and performance users chasing changes in muscle accrual, training output, and overall anabolic feel over time rather than an acute stimulant effect. The mechanism is not nitric oxide, ATP recycling, or CNS stimulation. The strategy is precursor delivery: supplying a hormone-related substrate that can be metabolized downstream into active androgenic compounds associated with the 19-nor family. In practical terms, users choosing this category are usually looking for support in lean mass phases, strength progression, and a denser, fuller training look across a multi-week run.

The dose is where the formula becomes more difficult to assess with precision. We know the total blend is 50mg, but Blackstone Labs does not disclose how much of that total comes from the base compound versus the decanoate and enanthate esters. That matters because exact milligram exposure determines how this product compares to other 19-NorDHEA formulas in the category. In other words, this is not a fully transparent panel. The ingredient identity is clear, but the internal allocation is hidden inside a proprietary blend. From an evidence-based standpoint, that is a real limitation.

The inclusion of multiple forms appears to be a delivery strategy rather than an attempt to broaden the active profile. The non-esterified compound would be expected to contribute more immediate availability, while decanoate and enanthate forms are typically positioned to alter release characteristics and extend the delivery curve. That does not make the formula fully time-released in a pharmaceutical sense, but it does suggest the formulator wanted more than a single raw 19-NorDHEA input. Supporting excipients like phosphatidylcholine and hydroxypropyl-beta-cyclodextrin likely serve formulation and solubility roles that can improve handling of lipophilic actives, though they are not a substitute for clinical bioavailability data.

As a system, this is a minimalist hormone-focused formula: one core active pathway, multiple forms of the same precursor, no built-in on-cycle support, no liver support, no estrogen management support, and no recovery infrastructure. That simplicity will appeal to users who want a dedicated 19-nor product they can place inside a larger stack, but it also means responsibility shifts to the user to plan support supplements and post-cycle strategy appropriately.

What should you expect? Day 1 is usually uneventful in terms of sensation. There is no meaningful stimulant hit, no pump surge, and no dramatic acute feel. Over 2-4 weeks, users in this category typically look for changes in training aggression, workload tolerance, body composition momentum, muscular fullness, and scale movement when paired with sufficient calories and progressive training. The formula is conceptually straightforward, but because the blend is proprietary and this category carries meaningful hormonal, health, and testing considerations, it is best approached by advanced users who understand exactly what they are buying.